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completed the necessary documentation. Thirty-seven of 42
(88%) patients experienced at least one IV PCA-related problem,
with an average of 3.3 problems per patient. The most common
problems were drug-related (79%), including dose adjustments,
syringe replacement, and medication changes. Patient-related
problems were also common (45%), and included the need for
patient re-education regarding IV PCA use, assisting patients in
using the on-demand button, and addressing side effects related
to opioid use. IV PCA line problems and pump-related problems
were observed in 14% and 12% of patients, respectively. CON-
CLUSIONS: IV PCA administration requires a complex series of
processes and coordination among several hospital departments.
Problems with IV PCA are common and require staff time and
effort to resolve.
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OBJECTIVES: To determine the cost-effectiveness of a combi-
nation tablet of tramadol/paracetamol (Zaldiar) versus tramadol
in the treatment of subacute low back pain in a Dutch Health
Care setting. The hypothesis was that higher drug costs for the
combination therapy are offset by a reduction of costs associated
with the treatment of side-effects. METHODS: Decision analy-
sis was used to model the health economic outcomes. A cost-
minimisation approach was appropriate since the efﬁcacy of the
two treatments proved to be the same in the dosages used. Prob-
abilities (side-effects), resource utilisation data (pain treatment
and treatment of side-effects), productivity losses and unit costs
were obtained from published literature, clinical trial reports,
Delphi panel and ofﬁcial price and tariff lists (Dutch costing
manual). The perspective taken was that of society and health
insurance. RESULTS: Compared with tramadol IR, savings with
combination therapy from a society perspective were 34.78€ per
patient for ten days’ treatment of subacute low back pain (costs
of combination therapy: 62.58€; with tramadol IR: 97.36€).
Savings with combination therapy from a health insurance per-
spective were 25.30€ (costs of combination therapy: 54.64€;
with tramadol IR: 79.94€). Sensitivity analyses conﬁrmed the
robustness of the model. CONCLUSIONS: The results show that
treatment with the combination tablet of tramadol/paracetamol
compared with tramadol IR is cost-saving and has fewer side-
effects. This is true despite the fact that with the dosages used
the daily drug costs of combination therapy are higher than those
of tramadol IR. The reason for the lower total therapy costs is
the lower incidence of side-effects with the combination tablet
of tramadol/paracetamol, resulting in favourable clinical and
economic beneﬁts.
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OBJECTIVES: The current treatment of neuropathic pain (NeP)
includes a wide range of drug and non-drug therapies, and
patient outcomes are not very satisfactorily. The aim of this study
was to assess the magnitude of, and to explore the relationship
between the health and economic burden of the condition in
patients treated at the specialist level. METHODS: Ninety-eigth
patients with NeP were included at random cross-sectionally in
4 pain centres, and were followed up prospectively during one
month. All medical resource use related to NeP as well as pain
scores (daily Visual Analogue Scale), were collected via patient
diaries. Quality of Life (MPI, MPQ and SF-36) was assessed at
start and at the end of the one month observation period. Costs
from the public insurance perspective were calculated by multi-
plying the medical resource use with charges. SF-36 scores were
transformed into utility values, using the SF-6D algorithm.
RESULTS: Patients had an average history of 4.5 years of NeP;
84% had peripheral NeP; 20% had mild pain, 80% moderate
or severe. The total monthly cost was 438.4€ (+/ 105.8). Hospi-
tal stays represented 57% of total costs. The utility at start was
0.550 (+/- 0.012) and at the end date 0.578 (+/- 0.012) (p =
0.005). A multivariate regression analysis showed an indepen-
dent and signiﬁcant inverse relationship between utility at start
and total cost (p = 0.011). In peripheral NeP, patients with mod-
erate to severe pain had a more than doubled cost compared to
patients with mild pain: 517€ (+/- 148) vs. 201€ (+/- 45) (p =
0.045). CONCLUSIONS: NeP is associated with rather utility
values in the order of magnitude of some cancer types. Higher
pain scores and lower utilities lead to higher cost of treatment.
A possible explanation for the slight but signiﬁcant increase in
utility is the increased attention within the study environment.
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OBJECTIVES: Aim of the survey was: 1) to identify character-
istics of patients with PND’s; 2) to quantify burden of health
resource utilisation among this patients; and 3) to investigate the
impact of PND’s and its treatment on productivity and daily
functioning. METHODS: In this cross-sectional, one-time survey
we focused on the documentation of self-reported functioning
and well-being, pain exerience, MD’s reported medication use,
productivity and employment status. Well established question-
aires / scals were used for data collection. RESULTS: A total of
202 patient questionnaires were eligible for data-analysis. Dia-
betic (n = 62) and Postherpetic (n = 33) neuropatic pain were
most prominent where 86% of the patients reported their worst
pain within the last 24 hours as moderate 33% or severe 53%
(all indications). The pain severity index results where nearly
similar but moderate was reported mostly (57%). EQ-5D-scores
was comparable for worst pain within the last 24 hours and pain
severity index and was low in patients reporting “severe pain
experience” (0.3/0.13). Ten percent (10%) of patients were early
retired, 12% were disabled due to neuropatic pain, 17% had to
reduce scheduled work and 27% of the patients reported a sus-
tantial reduction in work productivity because of their NeP.
Analgesics (77%) were prescribed most commonly followed by
antiepileptics (53%), antidepressants (37%) and Hypnotics
(30%). Combination is common. Patient satisfaction by using
the prescribed medication was high. In total, 21% were
“extremely satisﬁed” and 55% were “somewhat satisﬁed”.
CONCLUSIONS: Treatment of NeP should be optimized since
a high percentage of patients reported a considerable pain within
24h. However, it is astonishing that in general patients satisfac-
tion with their current treatment was high. The mismatch
